A recent study found that a drug for immune patients in children helped coronary patients recover faster, as it was approvedRuxolitinib For the treatment of leukocytosis(HLH) It is a severe systemic inflammatory syndrome amongst young adults that can be fatal, by calming the overactive immune system reaction..
According to the British Daily Mail newspaper, scientists from the Cincinnati Children’s Hospital in America say that 10 of the patients who received the drug experienced an improvement in their respiratory health compared to those who received a placebo, in addition to that the patients who did not receive ruxolitinib 14% more likely to die than those who died.
Medication is also usedruxolitinib For the treatment of bone marrow cancer, which helps control the immune system’s response and kills some types of cancerous cells, researchers hope the drug will help ward off cytokine storms, which is when the body not only resists the virus, but also attacks its cells and tissues.
Cytokine storms are also a common feature of children who fight HLH Secondary, which occurs when the first treatment for does not work HLH.
Dr. Gang Hwang, a cancer specialist at the Cincinnati Children’s Hospital, noticed the feature of the patients and decided to know if the drug used to treat one could treat the other.
“I contacted our research colleagues in Wuhan, explained our observations, and recommended that we test this drug to calm the cytokine storm in multiple infections in patients with disease,” Huang said. COVID-19 Severe. “
The disease was spreading very quickly and many people were dying, and we believed that the current clinical medicine would help save lives, so we worked to push it forward before there was an effective vaccine for everyone.
For the study, which was published in the Journal of Allergy and Clinical Immunology, the team looked at 43 hospitalized patients with coronavirus between February 9 and February 28..
Half of the patients were randomized to receive two doses per day by mouth from ruxolitinib In addition to standard care, the other half received placebo and standard care.
Patients who were treated with treatment were seen ruxolitinib Clinical improvements in a significantly shorter period of time than the control group, and in fact 90% of those who received Roxolytinib patients demonstrated CT scans within 14 days, and only 9% of patients from the control group experienced improvements in the same time frame.
Additionally, three patients in the control group died due to respiratory failure but none of the severely ill patients who received Roxolentinib died..
“This is the first treatment we know that seems to be working effectively to calm cytokine and inflammation in disease,” said Hwang. COVID-19 Severe, this is crucial so that we can develop and distribute an effective enough vaccine to help prevent people from getting infected, however it is noted that more studies are needed and that the second stage of your clinical trial Incyte And Novartis Consider how the drug might affect 400 seriously ill patients.
– .
